JCR Pharmaceuticals and Alexion, AstraZeneca Rare Disease, have entered into a license agreement for JCR’s JUST-AAV capsids to develop genomic medicines. JUST-AAV encompasses a range of vector types optimised for various target tissues—including liver-sparing, muscle-targeting, and brain-targeting variants—to expand the potential of AAV-based gene therapy. Under the terms of the agreement, Alexion may use the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!